Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 2
Where in China
- Red Blood Cell Diseases CenterTianjin, ChinaContact: Jianping Li, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT07010237
- Record updated
- 8 June 2025
- Original description
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.Read full original descriptionShow less
Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe/Severe Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.
Inclusion: Clinical diagnosis of VSAA/SAA; Age ≥65 years; Completion of all screening assessments; Must be able to swallow tablets; Signed informed consent (by patient or legal guardian if patient is incapacitated).
Exclusion: Prior treatment with ATG/high-dose cyclophosphamide; Prior cyclosporine/tacrolimus use >12 months; Prior TPO-RA therapy >3 months; Uncontrolled malignancies or conditions contraindicating ATG; Severe organ dysfunction (e.g., creatinine ≥177 μmol/L); Clonal cytogenetic abnormalities (excluding isolated -Y or +8); Investigator judgment of unsuitability.